Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis
APMIS · 2024
DOI: 10.1111/apm.13472 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift APMIS, 2024. Verfasst von M Meritxell Roca Mora und 6 weiteren Autor:innen. Beteiligte Einrichtung: International University of Catalonia, Barcelona, Spain. Hauptthemen laut MEDLINE: Nitriles, Polycythemia Vera, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to have lower thromboembolism rates compared to placebo in polycythemia vera (PV) patients. This meta‐analysis evaluates ruxolitinib's efficacy and safety against best available therapy (BAT) in patients with PV and in hydroxyurea‐resistant/intolerant PV patients. A comprehensive literature search was conducted up to November 2023. We compared ruxolitinib and BAT for efficacy and safety endpoints. Six studies involving 1061 patients were analyzed, with 620 on BAT and 441 on ruxolitinib. Ruxolitinib showed higher hematocrit control (p = 0.015) and treatment response (p = 0.04) compared to BAT. It also significantly improved Myeloproliferative Neoplasms‐Symptom Assessment Form scores (MPN‐SAF) (p < 0.01). Additionally, patients with PV treated with ruxolitinib had higher rates of nonmelanoma skin cancer (p < 0.01). In subgroup analyses focusing on patients resistant or intolerant to hydroxyurea, ruxolitinib maintained its efficacy, significantly improving treatment response (p < 0.01) and significant improvements in MPN‐SAF (p = 0.02) score when compared to BAT. The safety profile was consistent with the overall analyses, showing significantly reduced thromboembolism rates (p = 0.04), increased rates of anemia (p = 0.01), and increased herpes zoster infections (p = 0.02). Ruxolitinib outperforms BAT in PV and patients with PV‐resistant or intolerant to hydroxyurea, offering better hematocrit control and reducing symptomatic burden and thromboembolism risk. Yet, it is associated with higher rates of anemia, herpes infection, and skin cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International University of Catalonia, Barcelona, Spain.
- Faisalabad Medical University, Faisalabad, Pakistan.
- Universidade Federal de Ouro Preto, Ouro Preto, Brazil.
- Centro Universitário Lusíada, Santos, Brazil.
- Cardiff School of Medicine, Cardiff, Wales, UK.
- Federal University of the Southern Border, Passo Fundo, Brazil.
ORCID-Profile: M Meritxell Roca Mora
Zitieren
APA
Roca Mora, M. M., Afzal, F., Guimaraes, C. R., Cunha, L. M., Godoi, A., Marcolin, P., & Valenzuela S, A. (2024). Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis. APMIS. https://doi.org/10.1111/apm.13472
Vancouver
Roca Mora MM, Afzal F, Guimaraes CR, Cunha LM, Godoi A, Marcolin P, et al. Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis. APMIS. 2024. doi:10.1111/apm.13472
BibTeX
@article{RocaMora2024,
author = {Roca Mora, M Meritxell and Afzal, Farhan and Guimaraes, Catharina Ribeiro and Cunha, Luisa Marin and Godoi, Amanda and Marcolin, Patrícia and Valenzuela S, Andrés},
title = {Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis},
journal = {APMIS},
year = {2024},
doi = {10.1111/apm.13472}
}
EUVIMED